Article info
PDFShort report
The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review
- Correspondence to Dr Carol Dryden, Department of Paediatrics, Wishaw General Hospital, Netherton Street, Wishaw ML2 0DP, UK; carol.dryden{at}lanarkshire.scot.nhs.uk
Citation
The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review
Publication history
- Received December 29, 2015
- Revised May 13, 2016
- Accepted May 16, 2016
- First published June 10, 2016.
Online issue publication
May 18, 2018
Article Versions
- Previous version (13 December 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/